Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin vs Anthracyclines in Children With Nephroblastoma
NCT03892330Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pegylated liposomal doxorubicin in Wilms tumor (WT) (4 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: Progression Free Survival at 5 years, Time to Treatment Failure at 5 years and 1 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Wilms tumor (WT)
Beyond the preview
Go deeper on NCT03892330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892330.